olmesartan has been researched along with Pulmonary Fibrosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimura, M; Ichikawa, Y; Inuzuka, K; Nakao, S; Nishizawa, Y; Tagami, A; Takato, H; Waseda, Y; Yasui, M | 1 |
1 other study(ies) available for olmesartan and Pulmonary Fibrosis
| Article | Year |
|---|---|
Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Bleomycin; Blood Cell Count; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Hydroxyproline; Imidazoles; Macrophage Inflammatory Proteins; Male; Mice; Mice, Inbred ICR; Pulmonary Fibrosis; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Tumor Necrosis Factor-alpha; Vasoconstrictor Agents | 2008 |